Efficacy and safety of dapagliflozin in HFrEF according to age: insights from DAPA-HF
Our Past President. Prof. Felipe Martinez participated as Speaker in the recent Annual Meeting of the AHA in Philadelphia. He presented Efficacy and safety of dapagliflozin in HFrEF according to age: insights from DAPA-HF in the Late Breaking Trials Main Session. It is a substudy of the “DAPA-HF Trial” already presented and published, and where he is also a co-author.
The objective was to examine the efficacy and safety of dapagliflozin according to age in a post hoc analysis of DAPA-HF, a placebo-controlled trial in which dapagliflozin was added to other guideline-recommended therapies in patients with HF and reduced ejection fraction (HFrEF).
The summary is that Dapagliflozin reduced the risk of worsening HF events and CV death, and improved symptoms, in patients with HFrEF, when added to standard therapy. These benefits were consistent across the range of ages studied.
The relative and absolute risk reductions in death and hospitalization were substantial and clinically important. The absolute benefits in older patients were large because they were at higher risk than younger patients.
Dapagliflozin was well tolerated, and the rate of treatment discontinuation was low, in all age groups. Dapagliflozin offers a new approach to the treatment of HFrEF, irrespective of age.